January 08, 2025--(BUSINESS WIRE)--MOMA Therapeutics, a clinical-stage biopharmaceutical company discovering and developing a new generation of precision therapeutics, today announced the in ...

MOMA-313 is under clinical development by Moma Therapeutics and currently in Phase I for Metastatic Pancreatic Cancer.

This year will also doubtlessly bring deals involving artificial intelligence and related technologies. Experts predict that ...

In January 2024, the Swiss pharma penned a $66 million upfront agreement to access Moma Therapeutics’ KnowledgeBase ADC platform across various cancers. That deal also came with the promise of $ ...

--(BUSINESS WIRE)--MOMA Therapeutics, a clinical-stage biopharmaceutical company discovering and developing a new generation of precision therapeutics, today announced the in-licensing of a ...

Moma Therapeutics is a biopharmaceutical company that discovers novel precision medicines to treat patients with unmet medical needs. The company is developing a drug discovery platform that considers ...

Moma Therapeutics Inc. has in-licensed a next-generation selective poly(ADP-ribose) polymerase 1 (PARP-1) inhibitor, now known as MOMA-989.

NEW YORK – MOMA Therapeutics on Wednesday said it added the next-generation PARP1 inhibitor MOMA-989 to its pipeline of drug candidates and anticipates filing an investigational new drug application ...

MOMA Therapeutics, a clinical-stage biopharmaceutical company discovering and developing a new generation of precision therapeutics, today announced the in-licensing of a next-generation selective ...